AMD’s AI Advantage May Just Be Getting Started
While the spotlight often shines brightest on Nvidia, another chipmaker has been clawing its way into the conversation and could soon be in a position to steal the show.
That company is Advanced Micro Devices (NASDAQ: AMD), and it’s gearing up to report second-quarter earnings early next month.
With the stock already up 34% this year,
» Read more about: AMD’s AI Advantage May Just Be Getting Started »
Read More
72 Year Old American Diner with 40% Upside?
While the world focuses on AI, the leaders over at Denny’s are snapping up shares as part of a buyback scheme. The move is perplexing at first glance with sales decidedly flat for some time and no obvious catalyst to spark growth on the top line near-term.
So, what exactly are the Board of Directors and management seeing in the numbers that makes the restaurant chain worthy of investing in?
» Read more about: 72 Year Old American Diner with 40% Upside? »
Read More
Tesla’s Wild Ride: How Low Could the EV Giant Go?
Shares of EV major Tesla (NASDAQ:TSLA) have been defying gravity for years, rewarding longtime shareholders with very remarkably healthy returns. This year, though, TSLA has retreated on a combination of weakening outlook and the growing controversies surrounding Elon Musk.
What’s pushing Tesla shares lower, and how much more could the EV giant fall if it can’t regain its footing?
» Read more about: Tesla’s Wild Ride: How Low Could the EV Giant Go? »
Read More
Is David’s Dividend Strategy Perfect For Today’s Market?
David Bahnsen – founder of The Bahnsen Group and author of The Case for Dividend Growth – centers his investment philosophy on dividend growth investing.
In his view, a fundamental mentality shift is needed where investors need to focus on the cash income their portfolio generates rather than obsessing over short-term market prices.
» Read more about: Is David’s Dividend Strategy Perfect For Today’s Market? »
Read More
How a $300 Mistake Opened a $1 Billion Market
Novo Nordisk, the pharmaceutical giant behind weight-loss blockbusters Ozempic and Wegovy, just let a key patent on semaglutide lapse in Canada because it forgot to pay a routine maintenance fee, the pharmaceutical equivalent of forgetting to renew your car registration.
As a result, generic versions of semaglutide, the active ingredient in both drugs,
» Read more about: How a $300 Mistake Opened a $1 Billion Market »
Read MoreThe Ivy
Is The Stock with Ticker AI Finally a Buy?
C3.ai shares are back at price levels investors haven’t seen since early 2023, and the reasons are downright concerning.
The artificial intelligence firm with ticker AI has endured a brutal year that began in January when the share price was cut in half. The torpedos keeping hitting the bow, as evidence by the latest business update that pointed to a steep revenue shortfall.
» Read more about: Is The Stock with Ticker AI Finally a Buy? »
Read MoreThe Spotlight
1 Dividend Powerhouse Built for the Long Haul
When investors talk about reliability in the energy sector, Enbridge (NYSE: ENB) belongs in a class of its own. For over seven decades, this Canadian pipeline and utility powerhouse has paid a dividend, an almost unheard-of feat in an industry known for boom-and-bust cycles.
Even more impressive is that it has raised its dividend for 30 consecutive years,
» Read more about: 1 Dividend Powerhouse Built for the Long Haul »
Read MoreThe Daily
12 Best Growth Stocks to Buy Now
Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!
AI is eating the world—and the machines behind it are ravenous.
Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy.